Invossa aftereffects course over to other gene therapy companies - (The Korea Herald via NewsPoints Desk)

  • According to a report, Korea's Ministry of Food and Drug Safety recently inspected six gene therapy firms, The Korea Herald reported Thursday.

  • The firms investigated in August and September included GC Green Cross Cell, Medipost, Tego Science and Corestem.

  • The news comes after regulators revoked approval of Kolon Life Science's Invossa in May after finding that the company delayed revealing that the cells used in the therapy had been mislabelled.

  • Specifically, the firm discovered that the cells were derived from the kidneys opposed to the cartilage as previously documented.

  • The FDA has called for the Kolon to replace the kidney-derived cells with cartilage-derived cells.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.